Circular 45/2026/TT-BYT amends Vietnam's GMP rules: radiopharmaceuticals, investigational drugs and change control — effective 1 January 2027
The Ministry of Health issued Circular 45/2026/TT-BYT on 1 November 2026, amending Circular 28/2025/TT-BYT on good manufacturing practice for medicines and drug materials. It adds WHO-GMP for investigational drugs and a GMP standard for radiopharmaceuticals made in hospitals, rewrites change control, tightens follow-up of inspection findings and gives foreign plants a way to keep their EU-GMP listing current. It takes effect on 1 January 2027.
On 1 November 2026 the Ministry of Health issued Circular 45/2026/TT-BYT, amending 15 points of Circular 28/2025/TT-BYT, the main rulebook on good manufacturing practice (GMP) for medicines and drug materials in Vietnam. The changes take effect on 1 January 2027. The most visible additions are two new GMP standards — WHO-GMP for investigational and clinical-trial drugs (new Annex XII) and an IAEA/WHO-based standard for radiopharmaceuticals produced in hospitals (new Annex XIII). For established manufacturers, including foreign plants, the practical changes are in change control, follow-up of inspection findings and the publication of EU-GMP status.
What the document is
- Circular 45/2026/TT-BYT, signed on 1 November 2026 by Deputy Minister of Health Do Xuan Tuyen on the proposal of the Drug Administration of Vietnam (DAV) and the Traditional Medicine Administration.
- Legal basis: the Pharmacy Law (Law 105/2016/QH13, as amended by Law 44/2024/QH15), Decree 163/2025/ND-CP and Decree 313/2026/ND-CP on the Ministry's functions.
- It amends Circular 28/2025/TT-BYT of 1 July 2025. It replaces Annexes VI, VII, IX, X and XI and adds Annexes XII and XIII. It also amends one clause of Circular 18/2019/TT-BYT on GMP for health supplements.
What changes — new GMP standards
- Investigational drugs (Articles 2–3): sites making investigational drugs or drugs for clinical trials apply WHO-GMP for investigational products, set out in new Annex XII (Article 3(1)(dd) and Article 4(1) of Circular 28 as amended). WHO updates to this guideline are handled like PIC/S and EU updates: a manufacturer that wants to apply an update not yet posted by the Ministry sends the English text to DAV, which posts it within 10 days (Article 3(4)(b)).
- Radiopharmaceuticals made in hospitals (Articles 1–3, 10): new definitions separate production (making isotopes with a cyclotron and synthesising radiopharmaceuticals from them) from compounding (generator elution, labelling, dose dispensing and dilution under Circular 30/2021/TT-BYT). Healthcare facilities that produce radiopharmaceuticals apply new Annex XIII, a translation of the IAEA/WHO guideline on GMP for radiopharmaceutical products, and file a GMP evaluation request with a site master file (Article 13(2)).
- High-risk products (Article 3(4)): radiopharmaceuticals and radioactive drug materials join beta-lactams, cytotoxics, contraceptive sex hormones, vaccines and live biologicals on the list of products that need dedicated lines. A dedicated line now expressly includes separate utility systems as well as separate premises and equipment.
What changes — herbal, traditional and shared lines
- Herbal and traditional medicines (Article 3(2)–(3)): Article 4 of Circular 28 is reorganised so that each type of site maps to one GMP text. Herbal medicines use Annex V. Herbal-derived materials in modern dosage forms use Annex V or Part II of Annex VI; in traditional dosage forms, Part I of Annex VI. Traditional medicines in traditional forms (extracts, pills, powders, medicated wines, tinctures) use Part I of Annex VI; modern forms (capsules, tablets, granules and others) use Part II. Facilities that pre-process and process medicinal materials — a newly defined category — use Annex VII, which is now titled GMP for medicinal materials.
- Over-the-counter (OTC) plants making health supplements (Article 3(5)): an OTC-only chemical-drug plant may still make herbal medicines, traditional medicines and health supplements in its certified dosage forms, but no longer probiotic health supplements.
- Probiotic lines (Article 3(6)): a dedicated probiotic line may make materials and health supplements containing the same live microorganism, now also when combined with vitamins.
What changes — change control (Article 8, rewriting Article 11)
Article 11 is replaced by a tiered list:
- New Pharmacy Business Eligibility Certificate: changes under Article 36(1)(b) of the Pharmacy Law to the factory, warehouse or QC laboratory, or a switch from herbal/traditional scope to OTC chemical drugs.
- Adjusted certificate: a switch between full chemical-drug scope and OTC-only scope, in either direction. Production in the new scope may start only after the certificate is adjusted.
- Change report (Form 06) plus on-site evaluation: moving or adding a factory at the same business location; expansion or major re-layout; for sterile manufacturers, partial-line rework, key equipment and utility changes. New: moving or adding warehouses (materials, primary packaging, finished goods) or the microbiology testing area at the same location.
- Change report only: the same partial-line, equipment and utility changes at non-sterile sites, plus — new — expansion or major rework of warehouses and the microbiology area, and utility changes affecting storage or test conditions. If the report does not show continued compliance, the authority can carry out an unannounced evaluation.
- Vaccine makers must notify DAV with a risk assessment before major structural, equipment or utility changes or before running other products on a certified vaccine line. DAV objects in writing within 15 days if it disagrees.
What changes — EU-GMP listing of foreign plants (Article 11(10))
Plants rated EU-GMP or equivalent by a stringent regulatory authority (SRA) can still ask to be listed on the Ministry's portal. The new point is how a listing stays valid after the certificate date shown on the portal passes. It stays valid if the manufacturer either (i) has filed a request to publish the renewed certificate, or (ii) supplies its own search result from the English-language website or database of the authority concerned. The search must be done after the published expiry date, stamped by the manufacturer and sent with the link. The manufacturer is fully legally responsible for these documents; agencies relying on them check the link.
What changes — inspections and corrective actions (Articles 4–7, 9)
- Inspection steps (Article 4): the team inspects each line; a site performing only some stages is assessed only on those stages. The closing meeting must discuss any disagreement, and the signed inspection record (Form 03, Annex X) must list deficiencies, their grading and any unresolved points.
- Corrective action reports (Articles 5, 7): reports must include evidence for deficiencies already closed and a plan with committed deadlines for open ones. The 45-day, 20-day and 135-day deadlines stay. The authority re-inspects on site the corrective actions for the major deficiencies listed in amended Annex IX section II — mainly changes to premises, production equipment, utilities, warehouses, sampling areas and microbiology labs — or where the paperwork is unclear.
- Grading (amended Annex IX): level 1 — no critical or major deficiencies; level 2 — no critical, 1 to 6 major; level 3 — sites with two or more lines, no critical, 7 to 13 major; level 4 — at least one critical, or 7+ major deficiencies (one line) or 14+ (two or more lines). Any line directly linked to 7+ major deficiencies is rated level 4. Level-4 findings can now suspend a single line rather than the whole site.
- Unannounced and surveillance evaluations (Article 9, rewriting Article 12): triggers now include insufficient change reports and incidents or substantiated complaints received in writing, by hotline or through the media, in addition to recalls, serious adverse reactions, serious violations and missing annual reports. Level-3 sites (after corrective actions are accepted), level-4 sites (after restarting) and sites judged at risk get at least one unannounced evaluation within 3 years. The annual November plan now covers surveillance evaluations as well as periodic ones (Article 6).
- Inspection teams (Article 12): may include university experts and, where needed, representatives of other agencies.
Health supplements on drug lines (Article 13; Article 15(2))
The Vietnam Food Administration (VFA) gets an explicit role. It leads checks of GMP compliance for health supplements made on drug production lines and works with DAV and the Traditional Medicine Administration. Circular 18/2019/TT-BYT is amended to match. Drug manufacturers that also make health supplements must report that production to the receiving authority and to VFA before they start. They also report their drug, herbal, traditional-medicine and supplement output to DAV, the Traditional Medicine Administration and VFA.
Effective date and transition (Article 15)
- Effective: 1 January 2027.
- Dossiers already filed with the receiving authority before that date — eligibility certificates, GMP evaluations, periodic re-evaluations and change reports — are processed under Circular 28/2025/TT-BYT, or under the amended rules if the manufacturer asks.
- Healthcare facilities producing radiopharmaceuticals must meet Annex XIII by 1 November 2028 at the latest.
What companies should do
- Domestic manufacturers: map planned 2027 projects (warehouse moves, microbiology-lab works, utility upgrades) to the new Article 11 tiers. Storage and lab changes now need a change report, and relocations or additions need an on-site evaluation. Decide whether any dossier due around year-end is better filed before 1 January 2027.
- OTC-only plants making supplements: stop planning probiotic supplements on OTC lines; check that supplement production is reported to VFA before it starts.
- Foreign manufacturers relying on EU-GMP/SRA listing: track the expiry date shown on the DAV portal. Keep either a pending update request or a stamped self-search result with the authority's link ready for importers and registration files.
- CAPA practice: build closure evidence (records, photos, video, certificates) into corrective action reports. For premises, equipment, utility, warehouse and microbiology-lab findings, expect an on-site verification.
- Clinical-trial sponsors and CDMOs: check that sites supplying investigational drugs in Vietnam work to WHO-GMP for investigational products (Annex XII).
- Hospitals with nuclear medicine units: plan the gap assessment against Annex XIII before the 1 November 2028 deadline.
What is unclear
- The official PDF does not show the circular number and date in its text layer; they appear only in the signature stamps. The number 45/2026/TT-BYT, the 1 November 2026 issue date and the 1 January 2027 effective date are as listed on the Government legal-document portal.
- The grading thresholds are from the amended Annex IX; we have not compared them line by line with the 2025 version.
- Annex XIII is a translation of the IAEA/WHO guideline. It does not say how compounding-only nuclear medicine departments (generator elution and labelling) are treated, beyond the new definition.
- How the self-search route for EU-GMP status will be accepted in practice by DAV and by importers' customs and registration staff.
Sources
- Circular 45/2026/TT-BYT — Government legal-document portal entry (issued 1 November 2026, effective 1 January 2027): https://vanban.chinhphu.vn/?docid=220160&pageid=27160
- Signed text: https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/45-byt.signed.pdf
- Annexes (signed PDFs): VI https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_6.signed.pdf · VII https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_7.signed.pdf · IX https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_9.signed.pdf · X https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_10.signed.pdf · XI https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_11.signed.pdf · XII https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_12.signed.pdf · XIII https://datafiles.chinhphu.vn/cpp/files/vbpq/2026/11/phu_luc_13.pdf
- Secondary (context only): Suc khoe & Doi song, 4 November 2026 — https://suckhoedoisong.vn/tieu-chuan-gmp-cho-hoat-dong-san-xuat-thuoc-phong-xa-tu-1-1-2027-169261103144002763.htm
- Medibase related: <a href="/glossary/gmp/">GMP (glossary)</a>, <a href="/medicine/regulatory/">Medicine regulatory overview</a>, <a href="/medicine/traditional-medicine/">Traditional medicine guide</a>, <a href="/medicine/clinical-trials-be/">Clinical trials and bioequivalence guide</a>, <a href="/medicine/vaccines-biologicals/">Vaccines and biologicals guide</a>, <a href="/news/draft-amendments-to-pharmacy-law-decree-163-2025-nd-cp-consultation-closed-2-november-2026/">Draft amendments to Decree 163/2025/ND-CP</a>, <a href="/news/thong-tu-32-2026-tt-byt-dang-ky-luu-hanh-thuoc/">Circular 32/2026/TT-BYT on drug registration</a>.